Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) EBT (2020 - 2025)

Tango Therapeutics has reported EBT over the past 6 years, most recently at -$38.8 million for Q4 2025.

  • Quarterly results put EBT at -$38.8 million for Q4 2025, down 3.14% from a year ago — trailing twelve months through Dec 2025 was -$101.6 million (up 21.91% YoY), and the annual figure for FY2025 was -$101.6 million, up 21.91%.
  • EBT for Q4 2025 was -$38.8 million at Tango Therapeutics, down from $15.9 million in the prior quarter.
  • Over the last five years, EBT for TNGX hit a ceiling of $15.9 million in Q3 2025 and a floor of -$39.8 million in Q1 2025.
  • Median EBT over the past 5 years was -$26.7 million (2023), compared with a mean of -$25.0 million.
  • Biggest five-year swings in EBT: crashed 956255.93% in 2021 and later skyrocketed 154.53% in 2025.
  • Tango Therapeutics' EBT stood at -$21.9 million in 2021, then tumbled by 32.65% to -$29.0 million in 2022, then decreased by 5.88% to -$30.7 million in 2023, then fell by 22.48% to -$37.6 million in 2024, then dropped by 3.14% to -$38.8 million in 2025.
  • The last three reported values for EBT were -$38.8 million (Q4 2025), $15.9 million (Q3 2025), and -$38.8 million (Q2 2025) per Business Quant data.